Assertio Holdings, Inc.

Assertio Holdings, Inc. is a commercial pharmaceutical company focused on bringing differentiated products to patients. The company's headquarters are located in Lake Forest, Illinois. Assertio's business model has historically involved growth through business development, including licensing, mergers, and acquisitions, to expand its portfolio of branded prescription products.

The company's portfolio primarily includes branded prescription medications across neurology, inflammation, pain, and oncology market segments. Key products have included INDOCIN (indomethacin) Suppositories and Oral Suspension, Otrexup (methotrexate) injection, Sympazan (clobazam) oral film, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) Liquid filled capsules, and OXAYDO (oxycodone HCI, USP) tablets.

Assertio Holdings, Inc. was acquired by Zydus Worldwide DMCC for $23.50 per share in an all-cash tender offer, with the merger completing on June 16, 2026. Following the acquisition, Assertio's common stock was delisted from Nasdaq. Prior to this, the company had been pursuing a strategy to build a differentiated oncology franchise. Mark Reisenauer serves as the Chief Executive Officer.